Program
porustobart
Also written as “HBM4003 and Triprilimab”, “Porustobart” and “HBM4003”.
Its studies are mostly in Colonic Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Harbour BioMed (Guangzhou) | 30 open or running | phase 1since Dec 8, 2020 | Dec 8, 2020 | none ahead |
| Harbour BioMed US | 10 open or running | phase 1since Oct 15, 2019 | Oct 15, 2019 | none ahead |
| Solstice Oncology | 11 open or running | phase 2since Sep 3, 2026 | Sep 3, 2026 | Sep 30, 2029phase 2 · NCT07808151 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 15, 2019First study: phase 1 study in Advanced Solid TumorNew to Harbour BioMed USHarbour BioMed US · NCT04135261 · 65 enrolled · Australia, China, Hong Kong
- Dec 8, 2020Harbour BioMed (Guangzhou)'s first study: phase 1 study in Solid TumorsNew to Harbour BioMed (Guangzhou)Harbour BioMed (Guangzhou) · NCT04727164 · 61 enrolled
- Apr 26, 2021Phase 1 study in Solid TumorHarbour BioMed (Guangzhou) · NCT04866485 · 66 enrolled
- Nov 23, 2021Phase 1 study in Solid TumorsHarbour BioMed (Guangzhou) · NCT05149027 · 67 enrolled
- Sep 3, 2026Solstice Oncology's first study: phase 2 study in Colonic NeoplasmsNew to Solstice OncologySolstice Oncology · NCT07808151 · 100 planned · United States, Belgium, Italy and more
Ahead
- Sep 30, 2029Primary completion: phase 2 study in Colonic NeoplasmsSolstice Oncology · NCT07808151
TargetBeta
“A recombinant human heavy chain only antibody (HCAb) directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4;CTLA4), ”NCIt, by rule
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tremelimumabrule | AstraZeneca | phase 3 | 47 |
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 16 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 11 |
| gotistobartrule | oncoc4-inc | phase 3 | 5 |
| zalifrelimabrule | Agenus | phase 2 | 6 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| GB268rule | eddingpharm-zhuhai-co-ltd | phase 2 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07808151Colonic Neoplasms · United States, Belgium, Italy and more | 2 | Recruiting | Solstice Oncology | Sep 30, 2029 | 100 |
| NCT05149027Solid Tumors | 1 | UNKNOWN | Harbour BioMed (Guangzhou) | May 30, 2024 | 67 |
| NCT04866485Solid Tumor | 1 | UNKNOWN | Harbour BioMed (Guangzhou) | Feb 2023 | 66 |
| NCT04727164Solid Tumors | 1 | UNKNOWN | Harbour BioMed (Guangzhou) | Nov 2023 | 61 |
| NCT04135261Advanced Solid Tumor · Australia, China, Hong Kong | 1 | Completed | Harbour BioMed US | Jan 17, 2023 | 65 |
How it is read
Names in the registry
- “HBM4003 and Triprilimab”, 2 entries
- “Porustobart”, 1 entry
- “HBM4003”, 1 entry
- “HBM4003 and pembrolizumab”, 1 entry
Codes read as this program: HBM4003.
Conditions, from the studies’ own filings
- Colonic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.